Literature DB >> 24790398

Retrospective analysis of azithromycin versus fluoroquinolones for the treatment of legionella pneumonia.

Jerod L Nagel, Rachel E Rarus, Alex W Crowley, Cesar Alaniz.   

Abstract

BACKGROUND: Legionella is often associated with life-threatening pneumonia that is responsible for significant morbidity and mortality. Fluoroquinolones (FQ) have demonstrated improved clinical outcomes or decreased complications compared with clarithromycin and erythromycin. However, there is limited data comparing outcomes of FQ to azithromycin (AZM), which exhibits better Legionella activity than erythromycin and clarithromycin.
METHODS: This single-center retrospective study compared clinical outcomes of patients with Legionella pneumonia (LP) treated with AZM versus FQ from January 1999 to May 2011.
RESULTS: A total of 41 patients were included in the analysis; 21 received FQ and 20 received AZM. Demographics, comorbidities, and disease severity were similar between groups. Mortality (9.5% vs. 5%, P > 0.99), time to clinical stability (15.89 days vs. 10.26 days, P = 0.09), length of hospitalization (19.29 days vs. 11.35 days, P = 0.06), and presentation of any complication (85.7% vs. 90%, P > 0.99) were similar between the FQ and AZM groups, respectively.
CONCLUSION: Azithromycin appears to have clinical efficacy similar to FQ for the treatment of Legionella pneumonia.

Entities:  

Keywords:  Legionella pneumophilia; Legionnaires’ disease; azithromycin; community-acquired pneumonia; levofloxacin; macrolides

Year:  2014        PMID: 24790398      PMCID: PMC4005125     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  14 in total

1.  Legionnaires disease and the updated IDSA guidelines for community-acquired pneumonia.

Authors:  Victor L Yu; Julio Ramirez; Jorge Roig; Miguel Sabria
Journal:  Clin Infect Dis       Date:  2004-12-01       Impact factor: 9.079

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 3.  Systematic review and metaanalysis: urinary antigen tests for Legionellosis.

Authors:  Toshihiko Shimada; Yoshinori Noguchi; Jeffrey L Jackson; Jun Miyashita; Yasuaki Hayashino; Toru Kamiya; Shin Yamazaki; Tadashi Matsumura; Shunichi Fukuhara
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

4.  Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.

Authors:  A T Griffin; P Peyrani; T Wiemken; F Arnold
Journal:  Int J Tuberc Lung Dis       Date:  2010-04       Impact factor: 2.373

5.  Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.

Authors:  Analia Mykietiuk; Jordi Carratalà; Núria Fernández-Sabé; Jordi Dorca; Ricard Verdaguer; Frederic Manresa; Francesc Gudiol
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

6.  Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.

Authors:  Rosa Maria Blázquez Garrido; Francisco Javier Espinosa Parra; Loreto Alemany Francés; Rosa Maria Ramos Guevara; Juan Miguel Sánchez-Nieto; Manuel Segovia Hernández; José Antonio Serrano Martínez; Faustino Herrero Huerta
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

7.  Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing.

Authors:  Janet E Stout; Kelly Sens; Sue Mietzner; Asia Obman; Victor L Yu
Journal:  Int J Antimicrob Agents       Date:  2005-04       Impact factor: 5.283

8.  A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease.

Authors:  R B Fitzgeorge; S Lever; A Baskerville
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

Review 9.  Legionnaires' disease: clinical, epidemiological, and public health perspectives.

Authors:  R F Breiman; J C Butler
Journal:  Semin Respir Infect       Date:  1998-06

10.  Azithromycin in the treatment of Legionella pneumonia requiring hospitalization.

Authors:  Joseph F Plouffe; Robert F Breiman; Barry S Fields; Mark Herbert; Jill Inverso; Charles Knirsch; Antonia Kolokathis; Thomas J Marrie; Lindsay Nicolle; Douglas B Schwartz
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079

View more
  4 in total

Review 1.  Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

2.  Legionellosis in Transplantation.

Authors:  Shobini Sivagnanam; Steven A Pergam
Journal:  Curr Infect Dis Rep       Date:  2016-03       Impact factor: 3.725

3.  Nosocomial legionellosis and invasive aspergillosis in a child with T-lymphoblastic leukemia.

Authors:  Rhoikos Furtwängler; Uwe Schlotthauer; Barbara Gärtner; Norbert Graf; Arne Simon
Journal:  Int J Hyg Environ Health       Date:  2017-05-13       Impact factor: 5.840

4.  Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis.

Authors:  Annie S Jasper; Jackson S Musuuza; Jessica S Tischendorf; Vanessa W Stevens; Shantini D Gamage; Fauzia Osman; Nasia Safdar
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 20.999

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.